GlassScriptPhysician profile
Howard N Robinson
NPI 1922034925
$2,699.15
in general payments reported to CMS, 2019-2025
24 companies · $209 in 2025
The $209 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $73.85 · 2021: $380 · 2022: $689 · 2023: $886 · 2024: $340 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,161 · Education: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.91 |
| Education | $274.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $651.64 | 2019-2025 | |
| Janssen Biotech, INC. | $332.41 | 2021-2024 | Tremfya, Remicade, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $304.96 | 2019-2024 | Ilumya, Absorica Ld, Winlevi |
| Abbvie INC. | $194.68 | 2019-2024 | Rinvoq |
| Incyte Corporation | $170.61 | 2021-2024 | Opzelura |
| Genzyme Corporation | $146.51 | 2022-2024 | |
| Pfizer INC. | $145.48 | 2022-2023 | |
| Amgen INC. | $129.08 | 2019-2023 | Otezla |
| Arcutis Biotherapeutics, INC. | $114.86 | 2023-2024 | Zoryve |
| Organon LLC | $92.83 | 2025 | Vtama |
| Almirall LLC | $61.34 | 2022-2024 | Klisyri |
| E.R. Squibb & Sons, L.L.C. | $47.15 | 2022-2023 | Sotyktu |
| Dermavant Sciences, INC. | $45.30 | 2023 | Vtama |
| Nabriva Therapeutics, Plc | $40.47 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $35.08 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elekta, INC. | $34.91 | 2024 | Elekta Medical Linear Accelerator |
| Leo Pharma INC. | $28.50 | 2022 | |
| Galderma Laboratories, L.P. | $21.81 | 2025 | Aklief |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.50 | 2022 | |
| Biofrontera INC. | $18.28 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $17.82 | 2024 | Dupixent |
| Epi Health, LLC | $16.66 | 2022 | |
| Ucb, INC. | $16.53 | 2025 | Bimzelx |
| Medtronic, INC. | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.